bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. Our objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe and effective treatment options. Headquartered in Cambridge, Massachusetts, bluebird bio has operations in the U.S. and Europe.
UpGuard's CSTAR Score ranges from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.
Book a call with one of our specialists and we'll arrange a time for a demo.